PAD Profile : Mycophenolate mofetil - Scleritis

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Mycophenolate mofetil - Scleritis

PAD Profile : Mycophenolate mofetil - Scleritis

Keywords :

mycophenolic sodium, mycophenolic acid, mycophenolate sodium

Traffic Light Status

Status 1 of 1.

Status :

Amber

Formulations :

Capsules
Gastro-resistant tablets
Oral suspension
Tablets

Trust Alignment :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

BNF NICE SPC

Comments :

No comments returned.

Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Type

Document

Review Date

Shared Care

Shared Care Request letter (Specialist to Primary Care Prescriber) - National Shared Care - Appendix 1

Shared Care

Mycophenolate mofetil & mycophenolic acid for patients in adult services - National Shared Care protocol - updated August 2023

01 January 2025

Shared Care

Shared Care Agreement Letter (Primary Care Prescriber to Specialist)- National Shared Care - Appendix 2

Shared Care

Shared Care Refusal Letter (Primary Care Prescriber to Specialist)- National Shared Care - Appendix 3

Webpage

MHRA Drug Safety Update : Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis

Webpage

MHRA Drug Safety Update : Mycophenolate mofetil: pure red cell aplasia

Committee Recommendations

Date

Committee Name

Narrative

07 December 2022

Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the National Shared Care Protocol (with local adaptations) for mycophenolate mofetil and mycophenolic acid for patients within adult services (non-transplant indications)

Associated BNF Codes

11. Eye

11.04.02. Other anti-inflammatory preparations